RESEARCH Open Access



Can we get out of the COVID pandemic without adequate vaccination coverage in the pediatric population?

Susanna Esposito^{1*}, Rosanna Giordano², Giulia Paini², Matteo Puntoni³, Nicola Principi⁴ and Caterina Caminiti³

Abstract

Background: During the first and second COVID-19 pandemic waves, children, despite susceptible to SARS-CoV-2 infection, appeared at lower risk of severe disease, hospitalization, and death than adults and the elderly. Moreover, they seemed to play a minor role in the diffusion of the virus. The aim of this manuscript is to show epidemiological surveillance on COVID-19 incidence and hospitalization in the pediatric cohort in order to explain the importance of an adequate COVID-19 vaccination coverage in the pediatric population.

Methods: All subjects with documented SARS-CoV-2 infection diagnosed in Parma, Italy, between February 21st, 2020, and January, 31st, 2022, were recruited in this epidemiological surveillance. Diagnosis of infection was established in presence of at least one respiratory specimen positive for SARS-CoV-2 nucleic acid using a validated real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay.

Results: The number of COVID-19 pediatric cases remained very low and lower than that recorded in the general population between early February 2020 and the end of October 2021, despite in the last part of this period the Delta variant emerged. On the contrary, starting from November 2021, a sharp and significant increase in COVID-19 incidence in the pediatric population was evidenced. This was detected in all the age groups, although greater in the populations aged 5–11 and 12–17 years old. Interestingly, the peak in hospitalization rate was observed in children <5 years old, for whom COVID-19 vaccination is not approved yet. At the beginning of November 2021 among people older than 18 years of age 85.7% had completed the primary series of COVID-19 vaccine. Almost all the infants and pre-school children were susceptible. Until January 31st, 2022, 80.4% of adolescents aged 11–17 years had received at least two doses of COVID-19 vaccine and only 52.4% received the booster. Among children 5–11 years old, on January 31st, 2022, only 28.5% had received at least one vaccine dose.

Conclusions: Compared with adults and the elderly, presently a greater proportion of children and adolescents is susceptible to SARS-CoV-2 and could play a relevant role for the prolongation of the COVID-19 pandemic. Only a rapid increase in vaccination coverage of the pediatric populations can effectively counter this problem.

Keywords: COVID-19, COVID-19 vaccines, Epidemiology, Pediatric infectious diseases, SARS-CoV-2

¹ Department of Medicine and Surgery, Pediatric Clinic, University of Parma, Via Gramsci 14, 43126 Parma, Italy Full list of author information is available at the end of the article



Introduction

During the first and second COVID-19 pandemic waves, children, despite susceptible to SARS-CoV-2 infection, appeared at lower risk of severe disease, hospitalization, and death than adults and the elderly


© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, wist http://creativecommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: susanna.esposito@unimi.it

[1-3]. Moreover, although they could transmit the infection, they seemed to play a minor role in the diffusion of the virus [4]. Along with the negative physical and mental impact, this was one of the most important reasons why many experts opposed the school closure as a measure to contain virus circulation [5-7]. With the extension of the pandemic, the emergence of viral variants and the development and use of effective and safe vaccines, the role of the pediatric population in the spread of SARS-CoV-2 has changed substantially. The aim of this manuscript is to show epidemiological surveillance on COVID-19 incidence and hospitalization in the pediatric cohort in order to explain the importance of an adequate COVID-19 vaccination coverage in the pediatric population.

Methods

The province of Parma, a city with 194,417 inhabitants of whom 71,558 < 18 years of age, is located in Northern Italy and its health facilities were particularly involved in the first pandemic wave [8]. All subjects with documented SARS-CoV-2 infection diagnosed in Parma between February 21st, 2020, and January, 31st, 2022, were recruited in this epidemiological surveillance. Diagnosis of infection was established in presence of at least one respiratory specimen positive for SARS-CoV-2 nucleic acid using a validated real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay. Results of the specimens and on patients' outcome were provided by the Department of Public Health of AUSL Parma, that collects all the results of subjects tested for SARS-CoV-2 using RT-PCR in the city.



Results

Figure 1 shows epidemiological surveillance on COVID-19 incidence and hospitalization in the pediatric cohort. The number of COVID-19 pediatric cases remained very low and lower than that recorded in the general population between early February 2020 (i.e., the onset of the pandemic) and the end of October 2021, despite in the last part of this period the Delta variant emerged. On the contrary, starting from November 2021, a sharp and significant increase in COVID-19 incidence in the pediatric population was evidenced. This was detected in all the age groups, although greater in the populations aged 5-11 and 12-17 years old. Interestingly, the peak in hospitalization rate was observed in children <5 years old, for whom COVID-19 vaccination is not approved yet. Main reasons for hospitalization included diarrhea/vomiting (39%), respiratory distress/pneumonia (31%) and febrile seizures (11%).

Discussion

Omicron SARS-CoV-2 variant has increased transmissibility than the original SARS-CoV-2 [9] and it cannot be excluded that, despite children were less susceptible than adults to the original virus [10], they can be more easily infected by the new virus. Moreover, when Omicron appeared, a great number of adults and elderlies had a certain degree of protection against this virus as many of them had been already infected or vaccinated against SARS-CoV2. At the beginning of November 2021 among people older than 18 years of age living in Parma 85.7% had completed the primary series of COVID-19 vaccine. On the contrary, children and adolescents with adequate protection were quite few. Almost all the infants and pre-school children were susceptible as very few had been previously infected and none of them was vaccinated. Vaccination of adolescents aged 11-17 years was introduced in May 2021: until January 31st, 2022, 80.4% of them had received at least two doses of COVID-19 vaccine and only 52.4% received the booster. Among children 5-11 years old, for whom vaccine was authorized in December 2021, on January 31st, 2022, only 28.5% had received at least one vaccine dose and coverage remained less than 35% up to March 30th, 2022.

Conclusions

Compared with adults and the elderly, presently a greater proportion of children and adolescents is susceptible to SARS-CoV-2. Since, based on the global epidemiological data, health authorities currently tend to avoid further restrictive measures, it seems likely that children could play a relevant role for the prolongation

of the COVID-19 pandemic. Only a rapid increase in vaccination coverage of the pediatric populations can effectively counter this problem. Every effort must be made to persuade parents who are uncertain or against COVID-19 vaccines. Moreover, an effective and safe vaccine for children < 5 years old must be quickly approved for emergency use.

Abbreviation

RT-PCR: Real-time reverse-transcriptase polymerase-chain-reaction.

Acknowledgements

Not applicable.

Authors' contributions

SE designed the project and wrote the first draft of the manuscript. RG, GP and CC had in charge the epidemilogical surveillance. NP co-wrote the manuscript. MP and CC analysed the data and gave a substantial scientific contributions. All authors approved the final version of the manuscript.

Funding

None.

Availability of data and materials

All data generated during this study are included in the published article.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interest.

Author details

¹Department of Medicine and Surgery, Pediatric Clinic, University of Parma, Via Gramsci 14, 43126 Parma, Italy. ²Department of Public Health, AUSL Parma, Parma, Italy. ³Research and Innovation Unit, University Hospital of Parma, Parma, Italy. ⁴Università degli Studi di Milano, Milan, Italy.

Received: 1 May 2022 Accepted: 6 August 2022 Published online: 19 August 2022

References

- Sinha IP, Harwood R, Semple MG, Hawcutt DB, Thursfield R, Narayan O, et al. COVID-19 infection in children. Lancet Respir Med. 2020;8:446–7.
- Esposito S, Caramelli F, Principi N. What are the risk factors for admission to the pediatric inten-sive unit among pediatric patients with COVID-19? Ital J Pediatr. 2021;47:103.
- Esposito S, Marchetti F, Lanari M, Caramelli F, De Fanti A, Vergine G, et al. COVID-19 management in the pediatric age: consensus document of the COVID-19 working group in paediatrics of the Emilia-Romagna region (RE-CO-Ped), Italy. Int J Environ Res Public Health. 2021;18:3919.
- Li X. The role of children in transmission of SARS-CoV-2: a rapid review. J Glob Health. 2020;10:011101.
- Esposito S, Zona S, Vergine G, Fantini M, Marchetti F, Stella M, et al. How to manage children if a second wave of COVID-19 occurs. Int J Tuberc Lung Dis. 2020;24:1116–8.
- Esposito S, Principi N. School closure during the coronavirus disease 2019 (COVID-19) pandemic: an effective intervention at the global level? JAMA Pediatr. 2020;174:921–2.

- Esposito S. Pediatricians of Emilia-Romagna region, Italy. Manifesto of the pediatricians of Emilia-Romagna region, Italy, in favor of vaccination against COVID in children 5-11 years old. Ital. J Pediatr. 2022;48:40.
- 8. Caminiti C, Maglietta G, Meschi T, Ticinesi A, Silva M, Sverzellati N. Effects of the COVID-19 epidemic on hospital admissions for non-communicable diseases in a large Italian University-hospital: a descriptive case-series study. J Clin Med. 2021;10:880.
- Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, et al. Transmission dynamics and mutational prevalence of the novel SARS-CoV-2 omicron variant of concern. J Med Virol. 2022. https://doi.org/10. 1002/jmv.27611.
- 10. Cusenza F, Davino G, D'Alvano T, Argentiero A, Fainardi V, Pisi G, et al. Silence of the lambs: the immunological and molecular mechanisms of COVID-19 in children in comparison with adults. Microorganisms. 2021;9:330.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

